SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceXs stronger-than-expected quarterly results, first reported public-company profit and rapid growth in AI-compute revenue are driving attention, with traders debating whether the AI business justifies the companys heavy spending. Bulls point to the growth and outlook, while skeptics question cash burn, valuation and upcoming share unlocks; Tesla-merger speculation is an additional topic.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micros preliminary quarterly outlook substantially exceeded expectations, with stronger AI-server demand and improved gross margins driving the rally. Traders largely welcomed the update and speculated about a rerating or short covering, while others questioned whether the unaudited figures and margin gains will hold and flagged execution and cash-flow risks.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

SpaceXs results and comments about strong compute demand and scarce capacity have lifted sentiment toward Nebius and other AI cloud providers, challenging oversupply concerns. Bulls see support for the AI infrastructure demand thesis, while bears remain focused on financing risks and the sectors sharp selloff.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs quarterly results beat earnings expectations, but softer forward guidance and a lower advertising outlook drove a sharp post-earnings selloff. Traders are split between buying the dip as an overreaction and expecting further weakness amid slowing growth, ad-execution concerns, and streaming competition.

Nokia Oyj engages in the provision of network infrastructure, technology, and software services. It operates through the following segments: Mobile Networks, Network Infrastructure, Cloud and Network Services, and Nokia Technologies. The Mobile Networks segment offers technologies for Radio Access Networks (RAN) as well as Microwave Radio Links (MWR) for transport networks. The Network Infrastructure serves communication service providers, enterprises, webscales and public sector customers. The Cloud and Network Services segment builds around software and the cloud and is focused on driving leadership in cloud-native software and as-a-service delivery models, as demand for critical networks accelerates; and with strong market positions in communications software, private wireless networks, and cognitive (or intelligent) services. The Nokia Technologies segment, building on decades of innovation and R&D leadership in technologies used in virtually all mobile devices used today, is expanding the Nokia patent licensing business, reintroducing the Nokia brand to smartphones through brand licensing, and establishing a technology licensing business. The company was founded by Fredrik Idestam in 1865 and is headquartered in Espoo, Finland.

Nokia Corp - ADR

Nokia Corp

Nokias upcoming Q3 report is the main focus, with traders debating whether AI and cloud networking demand and recent AI-RAN partnerships will translate into stronger results. Some expect a positive surprise and a rerating, while others point to the stocks recent weakness and doubt that upbeat AI news will overcome pressure from its legacy telecom business.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabets weak, range-bound trading and its scheduled Oct. 28 earnings dominate discussion, with traders focused on whether cloud and AI growth can offset heavy investment spending and cash-flow concerns. Sentiment is split between dip-buyers and bearish traders pointing to persistent underperformance, technical risks, and broader pressure on tech stocks.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

SpaceXs strong AI-related results and data-center spending plans, alongside Super Micros sharply higher preliminary sales outlook, fueled discussion of renewed demand for Nvidia hardware and an after-hours rebound; traders also focused on Jensen Huangs GTC Berlin keynote. The reaction is divided, with bullish traders viewing the news as evidence that AI infrastructure spending remains strong while skeptics question its returns and Nvidias ability to sustain momentum.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

Attention centers on the expected completion of Compass Pathways rolling NDA submission for COMP360, its investigational psilocybin therapy for treatment-resistant depression, and the prospect of an accelerated FDA review. Traders are bullish on the approaching regulatory milestone and potential launch, while others are frustrated by the wait and point to volatile price action, broader biotech weakness, and uncertainty around timing and approval.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS shares are drawing attention after a sharp, high-volume rebound as traders position around the Phase 3 REGAL trials anticipated 80th survival event and final analysis of GPS in AML. Some speculate about a buyout or imminent data, but those claims are unconfirmed; others caution that the trial outcome remains uncertain and the move has occurred without a confirmed catalyst.

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Intuitive Surgical Inc

Intuitive Surgicals quarterly results beat expectations, but shares sold off as investors focused on a narrower procedure-growth outlook, planned pricing cuts, and a litigation-settlement charge. Traders are split between viewing the decline as an overreaction to solid business growth and seeing the guidance and pricing pressures as reasons for a more cautious outlook.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Agenus to Participate in Chardans 10th Annual Healthcare Investor Conference

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that Zack Armen, Head of Corporate Development and Investor Relations, will participate in a fireside chat and one-on-one investor meetings at Chardans 10th Annual Healthcare Conference: The Next 10 Years of...

Armenia Grants First Marketing Authorizations for Agenus BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the Ministry of Health of the Republic of Armenia has granted marketing authorizations for Botvymo (botensilimab, BOT) and Evamplix (balstilimab, BAL), each approved for use in combination with the other for...

Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus multifunctional, Fc-enhanced anti-CTLA-4 antibody, in...

Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that two posters highlighting research on botensilimab (BOT), an Fc-enhanced multifunctional anti-CTLA-4 antibody, in combination with balstilimab (BAL), an anti-PD-1 antibody, have been accepted for presentation at...

Kodiak Sciences, AMC Entertainment, Agenus And Other Big Stocks Moving Higher On Monday

U.S. stocks fell Monday, while Kodiak Sciences surged 174% after positive Phase 3 eye disease trial results; several small caps also rallied.read more...

Agenus to Participate in Upcoming September Investor Conferences

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that Robin Taylor, Ph.D., Chief Commercial Officer, and Zack Armen, Head of Corporate Development and Investor Relations, will participate in fireside chats and one-on-one investor meetings at two upcoming investor...

Agenus Announces Peer-Reviewed Publication Linking BOT+BALs Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the peer-reviewed publication of mature Phase 1b results from the fully enrolled C-800-01 cohort evaluating botensilimab (BOT), a multifunctional Fc-enhanced antiCTLA-4 antibody, plus balstilimab (BAL), an antiPD-1...

Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the peer-reviewed publication of updated results from the investigator-sponsored Phase 2 NEST trial evaluating neoadjuvant botensilimab (BOT), Agenus multifunctional, Fc-enhanced anti-CTLA-4 antibody, and...

Agenus (AGEN) Reports Q2 Loss, Tops Revenue Estimates

Agenus (AGEN) delivered earnings and revenue surprises of -120.00% and +1.52%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today reported financial results for the second quarter ended June 30, 2026, and provided an update on its financing-supported strategy to advance botensilimab (BOT), a multifunctional, Fc-enhanced anti-CTLA-4 antibody, plus...

This account has been verified as an official AGEN representative.

Verified Account

Agenus Communications

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.

Agenus Inc

AGEN Stock Eyes Best Day Ever Following Strategic Shift To Earlier Colon Cancer Treatment

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>Net proceeds from the financing are slated to fund a late-stage colon cancer clinical trial and potentially provide cash runway through 2031.</li><li>Agenus is also shifting its main drug combination to treat high-risk, earlier-stage colon cancer before surgery.&nbsp;</li><li>The condition represents a potential U.S. market opportunity of more than $7 billion annually, Agenus said.</li></ul><p><br>Agenus (AGEN) shares jumped 100% on Monday after the company announced an oversubscribed private placement of up to $340 million and a strategic pivot to prioritize its lead program in earlier-stage colon cancer.</p><p>The stock is now on track for its best day ever, if gains hold.</p><h2 class="st-heading-2">Financing Details</h2><p>Agenus is raising up to $340 million from investors through a private deal. It expects to receive about $85 million soon, with the potential for another $255 million later if investors buy more shares.</p><p>Net proceeds from the financing are slated to fund a late-stage colon cancer clinical trial and potentially provide cash runway through 2031.</p><p>The company had just $35.0 million in cash and cash equivalents as of March 31.</p><h2 class="st-heading-2">New Pipeline Focus</h2><p>Agenus is shifting its main drug combination (botensilimab plus balstilimab) to treat high-risk earlier-stage colon cancer before surgery, the company said. It now plans a large, late-stage study in the patient population, with the first patient expected to be dosed in the first quarter of 2027. The condition represents a potential U.S. market opportunity of more than $7 billion annually, Agenus said.</p><p>At the same time, Agenus is stopping financial support for a different study in patients with more advanced colon cancer. Earlier, smaller studies of the drug combination showed promising results, with many patients responding well to the treatment, it noted.</p><h2 class="st-heading-2">Expert Takeaway</h2><p>H.C. Wainwright analyst Emily Bodnar raised the firm’s price target on Agenus to $30 from $23 and kept a ‘Buy’ rating on the shares. H.C. Wainwright views the shift in strategy as favorable, saying there is currently no standard of care in neoadjuvant treatment for the condition. The firm’s new price target represents a potential upside of about 796% from the stock’s last closing price.</p><p>On X, the investor commonly referred to as ‘Pharma bro,’ Martin Shkreli wrote, “short $AGEN - PIPE does not change bleak outlook. should trade back to PIPE price.”</p><h2 class="st-heading-2">How Did AGEN Retail Traders React?</h2><p>On Stocktwits, retail sentiment around AGEN stock rose from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘normal’ to ‘extremely high’ levels.</p><p>A Stocktwits user expressed optimism for the pipeline pivot, increasing the market potential of the company’s drug combination.</p><p><stembedurl>https://www.stocktwits.com/jcilip/message/658917933</stembedurl></p><p>Another user voiced hopes for a further rally.</p><p><stembedurl>https://www.stocktwits.com/M105/message/658921495</stembedurl></p><p>According to data from Koyfin, both the analysts covering AGEN rate it a ‘Buy.’ The 12-month average price target on the stock is $15.50, representing a potential upside of 363% from the stock’s Friday close.</p><p><a href="https://stocktwits.com/symbol/AGEN">AGEN stock</a> has more than doubled year-to-date.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/kvue-stock-dips-after-court-revives-tylenol-autism-lawsuits/cZmzDliR7Yj">KVUE Stock Dips After Court Revives Tylenol Autism Lawsuits</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Agenus logo is displayed on the screen of the tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Agenus expects to receive about $85 million soon under a placement, with the potential for another $255 million later. 

iShares Russell 2000 ETF

Vanguard Total Stock Market ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$6.42
Prev Close	$6.18
Open	$6.10
Dividend Yield	0.00%
50-Day Moving Average	$7.70
Beta	1.93
Avg. Volume	1.06M
PE Ratio	2.42

52-Week High	$10.31
52-Week Low	$2.71
Market Capitalization	$279.1M
EPS (Annual)	-$0.0034
Price to Book	-1.37
Revenue Per Employee	$1.41M

Feed

News

Sentiment

Earnings

Fundamentals

Info

AGEN Fundamentals